Mabpharm Limited (HKG:2181)

Mabpharm Statistics

Total Valuation

Mabpharm has a market cap or net worth of HKD 2.27 billion. The enterprise value is 2.51 billion.

Market Cap	2.27B
Enterprise Value	2.51B

Important Dates

The last earnings date was Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Mabpharm has 4.12 billion shares outstanding. The number of shares has increased by 38.54% in one year.

Current Share Class	4.12B
Shares Outstanding	4.12B
Shares Change (YoY)	+38.54%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	49.95%
Owned by Institutions (%)	0.00%
Float	941.30M

Valuation Ratios

The trailing PE ratio is 49.42.

PE Ratio	49.42
Forward PE	n/a
PS Ratio	3.15
PB Ratio	12.96
P/TBV Ratio	33.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	39.48
EV / Sales	3.49
EV / EBITDA	38.46
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.81, with a Debt / Equity ratio of 2.08.

Current Ratio	0.81
Quick Ratio	0.49
Debt / Equity	2.08
Debt / EBITDA	5.57
Debt / FCF	n/a
Interest Coverage	0.46

Financial Efficiency

Return on equity (ROE) is 46.40% and return on invested capital (ROIC) is 0.70%.

Return on Equity (ROE)	46.40%
Return on Assets (ROA)	0.28%
Return on Invested Capital (ROIC)	0.70%
Return on Capital Employed (ROCE)	0.80%
Weighted Average Cost of Capital (WACC)	8.49%
Revenue Per Employee	1.88M
Profits Per Employee	166,000
Employee Count	383
Asset Turnover	0.60
Inventory Turnover	0.59

Taxes

Income Tax	-58.95M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.00% in the last 52 weeks. The beta is 0.94, so Mabpharm's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+10.00%
50-Day Moving Average	0.51
200-Day Moving Average	0.57
Relative Strength Index (RSI)	52.56
Average Volume (20 Days)	3,431,150

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mabpharm had revenue of HKD 718.98 million and earned 63.58 million in profits. Earnings per share was 0.01.

Revenue	718.98M
Gross Profit	638.36M
Operating Income	5.48M
Pretax Income	4.63M
Net Income	63.58M
EBITDA	65.27M
EBIT	5.48M
Earnings Per Share (EPS)	0.01

Balance Sheet

The company has 121.58 million in cash and 363.60 million in debt, with a net cash position of -242.02 million or -0.06 per share.

Cash & Cash Equivalents	121.58M
Total Debt	363.60M
Net Cash	-242.02M
Net Cash Per Share	-0.06
Equity (Book Value)	175.05M
Book Value Per Share	0.02
Working Capital	-111.00M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	60.84M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 88.79%, with operating and profit margins of 0.76% and 8.84%.

Gross Margin	88.79%
Operating Margin	0.76%
Pretax Margin	0.64%
Profit Margin	8.84%
EBITDA Margin	9.08%
EBIT Margin	0.76%
FCF Margin	n/a

Dividends & Yields

Mabpharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-38.54%
Shareholder Yield	-38.54%
Earnings Yield	2.80%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5